Nebulized LABA plus LAMA product improves FEV 1 , well tolerated in COPD

ORLANDO — Patients with COPD had larger improvements in FEV1 with a nebulized fixed-dose combination of indacaterol and glycopyrrolate vs. placebo, according to results presented at the American Thoracic Society International Conference.The long-acting beta-agonist indacaterol and the long-acting muscarinic antagonist glycopyrrolate make up AERO-007 (AeroRx Therapeutics), according to the